214 related articles for article (PubMed ID: 17283171)
41. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
42. Prevention of radiolysis of monoclonal antibody during labeling.
Chakrabarti MC; Le N; Paik CH; De Graff WG; Carrasquillo JA
J Nucl Med; 1996 Aug; 37(8):1384-8. PubMed ID: 8708780
[TBL] [Abstract][Full Text] [Related]
43. Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, isotype distribution, and induction of long term memory.
Skea DL; Barber BH
J Immunol; 1993 Oct; 151(7):3557-68. PubMed ID: 8376792
[TBL] [Abstract][Full Text] [Related]
44. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
[TBL] [Abstract][Full Text] [Related]
45. New insights into the mechanisms of action of radioimmunotherapy in lymphoma.
Ivanov A; Swann R; Illidge T
J Pharm Pharmacol; 2008 Aug; 60(8):987-98. PubMed ID: 18644192
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
47. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
48. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
49. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
[TBL] [Abstract][Full Text] [Related]
50. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
51. Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies.
Badger CC; Krohn KA; Shulman H; Flournoy N; Bernstein ID
Cancer Res; 1986 Dec; 46(12 Pt 1):6223-8. PubMed ID: 3779642
[TBL] [Abstract][Full Text] [Related]
52. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice.
Wei BR; Ghetie MA; Vitetta ES
Clin Cancer Res; 2000 Feb; 6(2):631-42. PubMed ID: 10690549
[TBL] [Abstract][Full Text] [Related]
53. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
Yao Z; Garmestani K; Wong KJ; Park LS; Dadachova E; Yordanov A; Waldmann TA; Eckelman WC; Paik CH; Carrasquillo JA
J Nucl Med; 2001 Oct; 42(10):1538-44. PubMed ID: 11585870
[TBL] [Abstract][Full Text] [Related]
54. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.
Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y
Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052
[TBL] [Abstract][Full Text] [Related]
55. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
56. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
Kaminski MS; Estes J; Zasadny KR; Francis IR; Ross CW; Tuck M; Regan D; Fisher S; Gutierrez J; Kroll S; Stagg R; Tidmarsh G; Wahl RL
Blood; 2000 Aug; 96(4):1259-66. PubMed ID: 10942366
[TBL] [Abstract][Full Text] [Related]
57. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Akabani G; Kennel SJ; Zalutsky MR
J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
[TBL] [Abstract][Full Text] [Related]
58. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.
DeNardo GL; DeNardo SJ; O'Grady LF; Levy NB; Adams GP; Mills SL
Cancer Res; 1990 Feb; 50(3 Suppl):1014s-1016s. PubMed ID: 2297713
[TBL] [Abstract][Full Text] [Related]
59. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy.
Fidarova EF; El-Emir E; Boxer GM; Qureshi U; Dearling JL; Robson MP; Begent RH; Trott KR; Pedley RB
Clin Cancer Res; 2008 May; 14(9):2639-46. PubMed ID: 18451227
[TBL] [Abstract][Full Text] [Related]
60. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
